What is MaxCyte's EBITDA?

MaxCyte (MXCT) reported EBITDA of -$5.14M in Q1 2026.

How has MaxCyte's EBITDA changed year-over-year?

MaxCyte's EBITDA increased by 54.1% year-over-year, from -$11.2M to -$5.14M.

What is the long-term trend for MaxCyte's EBITDA?

Over 4 years (2021 to 2025), MaxCyte's EBITDA has grown at a 29.8% compound annual growth rate (CAGR), from -$16.77M to -$47.56M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

MaxCyte MXCT EBITDA

EBITDA at other companies

Ginkgo BioworksDNA

-$58.58M+11.5%

Immix Biopharma, Inc.IMMX

-$10.71M-131%

Rapid Micro BiosystemsRPID

-$13.15M-21.6%

PDE

Pro-Dex, Inc.PDEX

$3.46M-12.5%

Bio-Rad LaboratoriesBIO

——

Thermo Fisher ScientificTMO

——

Other financials

Income statement

See full

Revenue$9.7M-7.1%

Gross profit$8.1M-9.1%

Operating income-$6.2M+49.7%

Net income-$4.8M+53.7%

EPS (diluted)-$0.04+60.0%

Balance sheet

See full

Cash & equivalents$14.6M-37.8%

Total debt$17.5M-7.1%

Total equity$167.9M-15.8%

Total assets$194.5M-15.4%

Cash flow

See full

Operating cash flow-$8.2M+43.3%

CapEx$72.0K-89.0%

Free cash flow-$8.2M+45.3%

Valuation

See full

Market cap$130.15M-46.8%

Enterprise value$133.08M-46.3%

P/S4×-2.8×

Profitability

See full

Gross margin80.5%-0.4pp

Operating margin-141.8%+6.4pp

Net margin-121.2%+12.3pp

FCF margin-90.9%+3.7pp

Returns & leverage

See full

Return on equity-21.3%+2.0pp

Debt / equity0.1×0.0×

Current ratio12×-0.2×

Where this comes from

Calculated from MaxCyte’s reported figures.

−$6.2Mebit+

$1.0MDepreciation Depletion & Amortization

=-$5.14M

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MaxCyte's EBITDA?: MaxCyte (MXCT) reported EBITDA of -$5.14M in Q1 2026.
How has MaxCyte's EBITDA changed year-over-year?: MaxCyte's EBITDA increased by 54.1% year-over-year, from -$11.2M to -$5.14M.
What is the long-term trend for MaxCyte's EBITDA?: Over 4 years (2021 to 2025), MaxCyte's EBITDA has grown at a 29.8% compound annual growth rate (CAGR), from -$16.77M to -$47.56M.
What does EBITDA mean?: Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.